FundedIQ
Biotechnology

Labster

Labster develops a platform that offers virtual laboratory simulations based on mathematical algorithms for students' e-learning. It is an internationally-focused company dedicated to the development of pioneering online tools for teaching science globally. Labster's primary product is an easily scalable online platform for teaching biotechnology that has been demonstrated to improve learning significantly over standard methods as well as substantially reduce costs. It is dedicated to bringing life science teaching to life. We think every day about the big picture of science education. The Labster platform is a 3D virtual learning environment based on a Virtual Lab. Labster includes molecular 3D animations, quiz questions, and background theory that engages students in an immersive, game-like multimedia experience. Structured around cases that explore both theory and experimental processes, our virtual labs offer advanced, unified scientific teaching solutions at a fraction of the cost of traditional labs. Labster was co-founded in 2011 by Mads Tvillinggaard Bonde and Michael Bodekaer in Copenhagen, Hovedstaden, Denmark.

www.labster.com Copenhagen, Denmark 251-500 employees
Total raised
$107M
Latest round: +78% of prior total
Rounds
2
Latest
Series C
Apr 2022

Labster develops a platform that offers virtual laboratory simulations based on mathematical algorithms for students' e-learning. It is an internationally-focused company dedicated to the development of pioneering online tools for teaching science globally. Labster's primary product is an easily scalable online platform for teaching biotechnology that has been demonstrated to improve learning significantly over standard methods as well as substantially reduce costs. It is dedicated to bringing life science teaching to life. We think every day about the big picture of science education. The Labster platform is a 3D virtual learning environment based on a Virtual Lab. Labster includes molecular 3D animations, quiz questions, and background theory that engages students in an immersive, game-like multimedia experience. Structured around cases that explore both theory and experimental processes, our virtual labs offer advanced, unified scientific teaching solutions at a fraction of the cost of traditional labs. Labster was co-founded in 2011 by Mads Tvillinggaard Bonde and Michael Bodekaer in Copenhagen, Hovedstaden, Denmark.

Labster has raised $107M across 2 rounds. Its most recent round was a Series C of $47.0M in Apr 2022. Full funding history, investors, and team are detailed below.

Funding history

2 rounds · 1 visible Unlock with plan

2 rounds on record — latest round shown, the rest unlock with a paid plan.

Date
Round
Amount
Lead investor
Apr 4, 2022
Series C
$47.0M

Unlock 1 earlier round — dates, amounts, round types — plus the lead investor for every round.

Unlock funding history →

People

Unlock with plan

Founders, executives, and decision-makers — sourced and refreshed weekly.

Name
Role
LinkedIn

See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.

Unlock people data →

Labster is featured in

Similar companies

Chromologics

Chromologics is a company that creates new and original food colorings utilizing natural ingredients. Derived from the Technical University of Denmark, this Danish biotech spin-out has established a biotech framework that employs fungi to generate exceptional and eco-friendly colorants.

Venture - Series Unknown $8.1M
Hemab

Hemab is focused on the development of bispecific antibodies for the treatment of rare bleeding disorders.

Series C $157M
SNIPR Biome

SNIPR Biome operates a discovery stage biotechnology company aiming to transform microbial disease treatment. Using CRISPR technology, the company can manipulate bacterial CRISPR machinery to target and eradicate harmful bacteria in vivo, creating medicines that specifically kill bacteria with certain DNA sequences for healthcare professionals.

Series B $40.8M
Dancann Pharma

Streaks AI is a leading developer of conversational AI platforms, pioneering innovative solutions for seamless and interactive communication. Specialising in creating advanced conversational interfaces, Streaks AI leverages artificial intelligence to enhance user experiences across various industries.

Series Unknown $310k
Cellugy

Cellugy is a biotechnology company that is changing industrial materials using biofabricated cellulose. With significant funding and a defined path for expansion, they are implementing EcoFLEXY in various industries like personal care and packaging to support environmental sustainability and combat plastic pollution.

Series Unknown $9.4M
Evaxion Biotech

Evaxion Biotech A/S is a company in the clinical stage that uses AI-immunology™ platform to understand the human immune system in order to create new immunotherapies for cancer and infectious diseases. They are working on a variety of product candidates, including personalized cancer immunotherapies that are currently in Phase I/IIa clinical trials, and vaccines for bacterial and viral infections, such as Methicillin-resistant S. aureus.

Series Unknown $80k
Neurescue

Neurescue, a company from Denmark that specializes in medical devices, is creating cardiovascular devices for emergency patients. Their initial product, the safeREBOA device, is the first computer-assisted catheter for aortic occlusion. The company aims to expand the use of intelligent procedures in the future.

Series Unknown
Enduro Genetics

Enduro Genetics is a genetic technology company dedicated to facilitating biomanufacturing, collaborating with clients to enhance current or novel cell lines and production strains. Utilizing the Enduro Sense technology platform, they create genetic enhancements that enhance the productivity and stability of cell lines and production strains. This technology offers significant advancements for both established and emerging bioprocesses.

Series A $12.3M
Commit Biologics

Commit Biologics is a biotechnology research company that was established in 2021 and is based in Aarhus, Denmark. They are focused on developing an innovative immunotherapy platform aimed at treating cancer.

Seed $5.7M
IO Biotech

IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. The pipeline of first-in-class immune modulating anti-cancer therapies is developed by a unique technology platform, T-win®, enabling the activation of T cells that are specific for immune-suppressive molecules. IO Biotech has a proven track record of progressing preclinical and clinical compounds. The two lead compounds targeting IDO and PD-L1 are in clinical development and several pipeline compounds are in pre-clinical phase.

Series Unknown $59.6M
Hervolution Therapeutics

Hervolution Therapeutics focuses on developing first-in-class immunotherapies to combat tumors from within. The company leverages Human Endogenous Retroviral proteins (HERVs) to create rationally designed immune therapeutics targeting the dark genome. Hervolution Therapeutics aims to address hidden enemies within the human body by pioneering innovative biotechnology solutions.

Series A $11.7M
Antag Therapeutics

Antag Therapeutics is a biotechnology company developing metabolic and anti-obesity therapeutic drugs. It offers the development of peptide-based GIP receptor antagonists in order to monitor dietary-related metabolic diseases through the infusion to decrease blood flow and lipid uptake in adipose tissue.

Series A $84.0M
Free · Every Monday

Know which startups just got funded. Every week.

Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.

Free. Sent every Monday. Unsubscribe anytime.